Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Identification of an Unfavorable Immune Signature in Advanced Lung Tumors from Nrf2-Deficient Mice.

Zhang D, Rennhack J, Andrechek ER, Rockwell CE, Liby KT.

Antioxid Redox Signal. 2018 Apr 16. doi: 10.1089/ars.2017.7201. [Epub ahead of print]

PMID:
29634345
2.

Chemoprevention of Preclinical Breast and Lung Cancer with the Bromodomain Inhibitor I-BET 762.

Zhang D, Leal AS, Carapellucci S, Zydeck K, Sporn MB, Liby KT.

Cancer Prev Res (Phila). 2018 Mar;11(3):143-156. doi: 10.1158/1940-6207.CAPR-17-0264. Epub 2017 Dec 15.

PMID:
29246957
3.

A BET Bromodomain Inhibitor Suppresses Adiposity-Associated Malignant Transformation.

Chakraborty D, Benham V, Jdanov V, Bullard B, Leal AS, Liby KT, Bernard JJ.

Cancer Prev Res (Phila). 2018 Mar;11(3):129-142. doi: 10.1158/1940-6207.CAPR-17-0262. Epub 2017 Dec 15.

PMID:
29246955
4.

Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer.

Belz JE, Kumar R, Baldwin P, Ojo NC, Leal AS, Royce DB, Zhang D, van de Ven AL, Liby KT, Sridhar S.

Theranostics. 2017 Sep 26;7(17):4340-4349. doi: 10.7150/thno.18563. eCollection 2017.

5.

Differential effects of the Nrf2 activators tBHQ and CDDO-Im on the early events of T cell activation.

Zagorski JW, Turley AE, Freeborn RA, VanDenBerg KR, Dover HE, Kardell BR, Liby KT, Rockwell CE.

Biochem Pharmacol. 2018 Jan;147:67-76. doi: 10.1016/j.bcp.2017.11.005. Epub 2017 Nov 15.

PMID:
29155145
6.

Synthetic oleanane triterpenoids enhance blood brain barrier integrity and improve survival in experimental cerebral malaria.

Crowley VM, Ayi K, Lu Z, Liby KT, Sporn M, Kain KC.

Malar J. 2017 Nov 14;16(1):463. doi: 10.1186/s12936-017-2109-0.

7.

Design, synthesis, and biological activity of second-generation synthetic oleanane triterpenoids.

Fu L, Lin QX, Onyango EO, Liby KT, Sporn MB, Gribble GW.

Org Biomol Chem. 2017 Jul 19;15(28):6001-6005. doi: 10.1039/c7ob01420a.

PMID:
28678272
8.

Nrf2-Dependent and -Independent Effects of tert-Butylhydroquinone, CDDO-Im, and H2O2 in Human Jurkat T Cells as Determined by CRISPR/Cas9 Gene Editing.

Zagorski JW, Maser TP, Liby KT, Rockwell CE.

J Pharmacol Exp Ther. 2017 May;361(2):259-267. doi: 10.1124/jpet.116.238899. Epub 2017 Mar 9.

9.

Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.

Leal AS, Williams CR, Royce DB, Pioli PA, Sporn MB, Liby KT.

Cancer Lett. 2017 May 28;394:76-87. doi: 10.1016/j.canlet.2017.02.021. Epub 2017 Feb 27.

PMID:
28254412
10.

NRF2 as an Emerging Therapeutic Target.

Copple IM, Dinkova-Kostova AT, Kensler TW, Liby KT, Wigley WC.

Oxid Med Cell Longev. 2017;2017:8165458. doi: 10.1155/2017/8165458. Epub 2017 Jan 31. No abstract available.

11.
12.

Rexinoids for prevention and treatment of cancer: opportunities and challenges.

Liby KT, Sporn MB.

Curr Top Med Chem. 2016 Jun 16. [Epub ahead of print]

PMID:
27320330
13.

CDDO-Me Redirects Activation of Breast Tumor Associated Macrophages.

Ball MS, Shipman EP, Kim H, Liby KT, Pioli PA.

PLoS One. 2016 Feb 26;11(2):e0149600. doi: 10.1371/journal.pone.0149600. eCollection 2016.

14.

The Rexinoids LG100268 and LG101506 Inhibit Inflammation and Suppress Lung Carcinogenesis in A/J Mice.

Cao M, Royce DB, Risingsong R, Williams CR, Sporn MB, Liby KT.

Cancer Prev Res (Phila). 2016 Jan;9(1):105-14. doi: 10.1158/1940-6207.CAPR-15-0325. Epub 2015 Nov 10.

15.

Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention.

Cao M, Onyango EO, Williams CR, Royce DB, Gribble GW, Sporn MB, Liby KT.

Pharmacol Res. 2015 Oct;100:135-47. doi: 10.1016/j.phrs.2015.07.024. Epub 2015 Jul 31.

PMID:
26238177
16.

Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis.

To C, Ringelberg CS, Royce DB, Williams CR, Risingsong R, Sporn MB, Liby KT.

Carcinogenesis. 2015 Jul;36(7):769-81. doi: 10.1093/carcin/bgv061. Epub 2015 May 4.

17.

Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.

Canfield K, Li J, Wilkins OM, Morrison MM, Ung M, Wells W, Williams CR, Liby KT, Vullhorst D, Buonanno A, Hu H, Schiff R, Cook RS, Kurokawa M.

Cell Cycle. 2015;14(4):648-55. doi: 10.4161/15384101.2014.994966. Erratum in: Cell Cycle. 2015;14(8):1339-41.

18.

PARP inhibitors for chemoprevention--reply.

To C, Sporn MB, Liby KT.

Cancer Prev Res (Phila). 2014 Nov;7(11):1172. doi: 10.1158/1940-6207.CAPR-14-0264. No abstract available.

19.

A synthetic triterpenoid CDDO-Im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancer.

So JY, Lin JJ, Wahler J, Liby KT, Sporn MB, Suh N.

PLoS One. 2014 Sep 17;9(9):e107616. doi: 10.1371/journal.pone.0107616. eCollection 2014.

20.

An efficient synthesis of methyl 2-cyano-3,12-dioxoursol-1,9-dien-28-oate (CDDU-methyl ester): analogues, biological activities, and comparison with oleanolic acid derivatives.

Fu L, Lin QX, Liby KT, Sporn MB, Gribble GW.

Org Biomol Chem. 2014 Jul 28;12(28):5192-200. doi: 10.1039/c4ob00679h.

PMID:
24915424
21.

The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice.

To C, Kim EH, Royce DB, Williams CR, Collins RM, Risingsong R, Sporn MB, Liby KT.

Cancer Prev Res (Phila). 2014 Jul;7(7):698-707. doi: 10.1158/1940-6207.CAPR-14-0047. Epub 2014 May 9.

22.

The synthetic triterpenoid (CDDO-Im) inhibits STAT3, as well as IL-17, and improves DSS-induced colitis in mice.

Fitzpatrick LR, Stonesifer E, Small JS, Liby KT.

Inflammopharmacology. 2014 Dec;22(6):341-9. doi: 10.1007/s10787-014-0203-2. Epub 2014 Apr 9.

PMID:
24715223
23.
24.

Synthesis and biological evaluation of amino acid methyl ester conjugates of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid against the production of nitric oxide (NO).

Onyango EO, Fu L, Cao M, Liby KT, Sporn MB, Gribble GW.

Bioorg Med Chem Lett. 2014 Jan 15;24(2):532-4. doi: 10.1016/j.bmcl.2013.12.034. Epub 2013 Dec 15.

PMID:
24388806
25.

Oral administration of a gemini vitamin D analog, a synthetic triterpenoid and the combination prevents mammary tumorigenesis driven by ErbB2 overexpression.

So JY, Wahler JE, Yoon T, Smolarek AK, Lin Y, Shih WJ, Maehr H, Uskokovic M, Liby KT, Sporn MB, Suh N.

Cancer Prev Res (Phila). 2013 Sep;6(9):959-70. doi: 10.1158/1940-6207.CAPR-13-0087. Epub 2013 Jul 15.

26.

Is lycopene an effective agent for preventing prostate cancer?

Sporn MB, Liby KT.

Cancer Prev Res (Phila). 2013 May;6(5):384-6. doi: 10.1158/1940-6207.CAPR-13-0026. Epub 2013 Mar 12.

27.

The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer.

Tran K, Risingsong R, Royce DB, Williams CR, Sporn MB, Pioli PA, Gediya LK, Njar VC, Liby KT.

Carcinogenesis. 2013 Jan;34(1):199-210. doi: 10.1093/carcin/bgs319. Epub 2012 Oct 6.

28.

Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease.

Liby KT, Sporn MB.

Pharmacol Rev. 2012 Oct;64(4):972-1003. doi: 10.1124/pr.111.004846. Epub 2012 Sep 10. Review.

29.

NRF2 and cancer: the good, the bad and the importance of context.

Sporn MB, Liby KT.

Nat Rev Cancer. 2012 Jul 19;12(8):564-71. doi: 10.1038/nrc3278. Review.

30.

Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease.

Kaidery NA, Banerjee R, Yang L, Smirnova NA, Hushpulian DM, Liby KT, Williams CR, Yamamoto M, Kensler TW, Ratan RR, Sporn MB, Beal MF, Gazaryan IG, Thomas B.

Antioxid Redox Signal. 2013 Jan 10;18(2):139-57. doi: 10.1089/ars.2011.4491. Epub 2012 Aug 13.

31.

Triterpenoid modulation of IL-17 and Nrf-2 expression ameliorates neuroinflammation and promotes remyelination in autoimmune encephalomyelitis.

Pareek TK, Belkadi A, Kesavapany S, Zaremba A, Loh SL, Bai L, Cohen ML, Meyer C, Liby KT, Miller RH, Sporn MB, Letterio JJ.

Sci Rep. 2011;1:201. doi: 10.1038/srep00201. Epub 2011 Dec 19.

32.

CDDO-methyl ester delays breast cancer development in BRCA1-mutated mice.

Kim EH, Deng C, Sporn MB, Royce DB, Risingsong R, Williams CR, Liby KT.

Cancer Prev Res (Phila). 2012 Jan;5(1):89-97. doi: 10.1158/1940-6207.CAPR-11-0359. Epub 2011 Sep 20.

33.

Proteomic analysis shows synthetic oleanane triterpenoid binds to mTOR.

Yore MM, Kettenbach AN, Sporn MB, Gerber SA, Liby KT.

PLoS One. 2011;6(7):e22862. doi: 10.1371/journal.pone.0022862. Epub 2011 Jul 27.

34.

Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis.

Neymotin A, Calingasan NY, Wille E, Naseri N, Petri S, Damiano M, Liby KT, Risingsong R, Sporn M, Beal MF, Kiaei M.

Free Radic Biol Med. 2011 Jul 1;51(1):88-96. doi: 10.1016/j.freeradbiomed.2011.03.027. Epub 2011 Mar 30.

35.

CDDO-imidazolide induces DNA damage, G2/M arrest and apoptosis in BRCA1-mutated breast cancer cells.

Kim EH, Deng CX, Sporn MB, Liby KT.

Cancer Prev Res (Phila). 2011 Mar;4(3):425-34. doi: 10.1158/1940-6207.CAPR-10-0153.

36.

New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress.

Sporn MB, Liby KT, Yore MM, Fu L, Lopchuk JM, Gribble GW.

J Nat Prod. 2011 Mar 25;74(3):537-45. doi: 10.1021/np100826q. Epub 2011 Feb 10. Review.

37.

The synthetic triterpenoid CDDO-Imidazolide suppresses experimental liver metastasis.

Townson JL, Macdonald IC, Liby KT, Mackenzie L, Dales DW, Hedley BD, Foster PJ, Sporn MB, Chambers AF.

Clin Exp Metastasis. 2011 Mar;28(3):309-17. doi: 10.1007/s10585-011-9374-z. Epub 2011 Jan 15.

PMID:
21234655
38.

Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer.

Liby KT, Royce DB, Risingsong R, Williams CR, Maitra A, Hruban RH, Sporn MB.

Cancer Prev Res (Phila). 2010 Nov;3(11):1427-34. doi: 10.1158/1940-6207.CAPR-10-0197. Epub 2010 Oct 19.

39.

Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer.

Nagaraj S, Youn JI, Weber H, Iclozan C, Lu L, Cotter MJ, Meyer C, Becerra CR, Fishman M, Antonia S, Sporn MB, Liby KT, Rawal B, Lee JH, Gabrilovich DI.

Clin Cancer Res. 2010 Mar 15;16(6):1812-23. doi: 10.1158/1078-0432.CCR-09-3272. Epub 2010 Mar 9.

40.

2-Cyano-3,10-dioxooleana-1,9(11)-dien-28-oic acid anhydride. A novel and highly potent anti-inflammatory and cytoprotective agent.

Honda T, Padegimas EM, David E, Sundararajan C, Liby KT, Williams C, Sporn MB, Visnick M.

Bioorg Med Chem Lett. 2010 Apr 1;20(7):2275-8. doi: 10.1016/j.bmcl.2010.02.007. Epub 2010 Feb 6.

41.

Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide.

Shin S, Wakabayashi J, Yates MS, Wakabayashi N, Dolan PM, Aja S, Liby KT, Sporn MB, Yamamoto M, Kensler TW.

Eur J Pharmacol. 2009 Oct 12;620(1-3):138-44. doi: 10.1016/j.ejphar.2009.08.022. Epub 2009 Aug 19.

42.

The triterpenoid CDDO-imidazolide confers potent protection against hyperoxic acute lung injury in mice.

Reddy NM, Suryanaraya V, Yates MS, Kleeberger SR, Hassoun PM, Yamamoto M, Liby KT, Sporn MB, Kensler TW, Reddy SP.

Am J Respir Crit Care Med. 2009 Nov 1;180(9):867-74. doi: 10.1164/rccm.200905-0670OC. Epub 2009 Aug 13.

43.

Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription.

Yang L, Calingasan NY, Thomas B, Chaturvedi RK, Kiaei M, Wille EJ, Liby KT, Williams C, Royce D, Risingsong R, Musiek ES, Morrow JD, Sporn M, Beal MF.

PLoS One. 2009 Jun 1;4(6):e5757. doi: 10.1371/journal.pone.0005757.

44.

Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice.

Yates MS, Tran QT, Dolan PM, Osburn WO, Shin S, McCulloch CC, Silkworth JB, Taguchi K, Yamamoto M, Williams CR, Liby KT, Sporn MB, Sutter TR, Kensler TW.

Carcinogenesis. 2009 Jun;30(6):1024-31. doi: 10.1093/carcin/bgp100. Epub 2009 Apr 21.

45.

Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice.

Sussan TE, Rangasamy T, Blake DJ, Malhotra D, El-Haddad H, Bedja D, Yates MS, Kombairaju P, Yamamoto M, Liby KT, Sporn MB, Gabrielson KL, Champion HC, Tuder RM, Kensler TW, Biswal S.

Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):250-5. doi: 10.1073/pnas.0804333106. Epub 2008 Dec 22.

46.

Genetic or pharmacologic amplification of nrf2 signaling inhibits acute inflammatory liver injury in mice.

Osburn WO, Yates MS, Dolan PD, Chen S, Liby KT, Sporn MB, Taguchi K, Yamamoto M, Kensler TW.

Toxicol Sci. 2008 Jul;104(1):218-27. doi: 10.1093/toxsci/kfn079. Epub 2008 Apr 15.

47.

A dicyanotriterpenoid induces cytoprotective enzymes and reduces multiplicity of skin tumors in UV-irradiated mice.

Dinkova-Kostova AT, Jenkins SN, Wehage SL, Huso DL, Benedict AL, Stephenson KK, Fahey JW, Liu H, Liby KT, Honda T, Gribble GW, Sporn MB, Talalay P.

Biochem Biophys Res Commun. 2008 Mar 21;367(4):859-65. doi: 10.1016/j.bbrc.2008.01.026. Epub 2008 Jan 17.

PMID:
18206646
48.

Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils.

Thimmulappa RK, Fuchs RJ, Malhotra D, Scollick C, Traore K, Bream JH, Trush MA, Liby KT, Sporn MB, Kensler TW, Biswal S.

Antioxid Redox Signal. 2007 Nov;9(11):1963-70.

49.

Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer.

Liby KT, Yore MM, Sporn MB.

Nat Rev Cancer. 2007 May;7(5):357-69. Epub 2007 Apr 19. Review.

PMID:
17446857
50.

Novel tricyclic compounds having acetylene groups at C-8a and cyano enones in rings A and C: highly potent anti-inflammatory and cytoprotective agents.

Honda T, Sundararajan C, Yoshizawa H, Su X, Honda Y, Liby KT, Sporn MB, Gribble GW.

J Med Chem. 2007 Apr 19;50(8):1731-4. Epub 2007 Mar 17.

Supplemental Content

Support Center